Development and validation of a prognostic nomogram for decompensated liver cirrhosis

Abstract

BACKGROUND

Decompensated liver cirrhosis (DLC) is a stage in the progression of liver cirrhosis and has a high mortality.

AIM

To establish and validate a novel and simple-to-use predictive nomogram for evaluating the prognosis of DLC patients.

METHODS

A total of 493 patients with confirmed DLC were enrolled from The First Affiliated Hospital of Nanchang University (Nanchang, Jiangxi Province, China) between December 2013 and August 2019. The patients were divided into two groups: a derivation group (n = 329) and a validation group (n = 164). Univariate and multivariate Cox regression analyses were performed to assess prognostic factors. The performance of the nomogram was determined by its calibration, discrimination, and clinical usefulness.

RESULTS

Age, mechanical ventilation application, model for end-stage liver disease (MELD) score, mean arterial blood pressure, and arterial oxygen partial pressure/inhaled oxygen concentration were used to construct the model. The C-indexes of the nomogram in the derivation and validation groups were 0.780 (95%CI: 0.670-0.889) and 0.792 (95%CI: 0.698-0.886), respectively. The calibration curve exhibited good consistency with the actual observation curve in both sets. In addition, decision curve analysis indicated that our nomogram was useful in clinical practice.

CONCLUSION

A simple-to-use novel nomogram based on a large Asian cohort was established and validated and exhibited improved performance compared with the Child-Turcotte-Pugh and MELD scores. For patients with DLC, the proposed nomogram may be helpful in guiding clinicians in treatment allocation and may assist in prognosis prediction.

Key Words: Decompensated liver cirrhosis; Nomogram; Prognosis; Child-Turcotte-Pugh score; MELD score

Core Tip: The overall survival of decompensated liver cirrhosis (DLC) has been one of the main concerns of patients and clinicians. In this research, we established a simple and effective nomogram including age, application of mechanical ventilation, model for end-stage liver disease (MELD) score, mean arterial blood pressure and arterial oxygen partial pressure/inhaled oxygen concentration. This nomogram had better prognostic value than the Child-Turcotte-Pugh and MELD scores. Moreover, the nomogram was validated in the internal cohort, and it may be helpful in guiding clinicians in treatment allocation and in predicting the prognosis of DLC.

INTRODUCTION

Decompensated cirrhosis (DLC) is characterized by the development of cirrhosis-related complications, such as ascites, gastroesophageal variceal bleeding, hepatic encephalopathy (HE), and severe jaundice[1]. Less than 1% of patients with acute DLC do not have any evidence of systemic inflammation[2]. Patients with DLC have a dismal prognosis, with a median survival of approximately 2 years[3]. Variceal bleeding is one of the most feared complications in patients with cirrhosis due to its deleterious impact on prognosis. Severe hemorrhage may cause ischemic hepatitis, which causes the release of inflammatory stimuli and may precipitate acute-on-chronic liver failure (ACLF)[4]. The course of DLC is often abruptly accelerated by the development of ACLF, which has a high short-term mortality[5]. Therefore, early recognition and timely treatment are significantly important to improving survival in DLC patients. A previous study confirmed that the Child-Turcotte-Pugh (CTP) score and model for end-stage liver disease (MELD) score were predictors of mortality in DLC patients[6,7]; However, many studies have revealed the poor predictive performance of these two scores when compared with other scores or biomarkers[8,9].

Nomograms are easy to use and can facilitate management-related decision making. Nomograms are widely applied as statistical prognostic models in medicine and could offer more individualized and accurate predictions than other models for numerous illnesses[10,11]. The purpose of this study was to determine the risk factors for short-term death from DLC and to construct a clinically useful nomogram to estimate individual prognosis.

MATERIALS AND METHODS

Study populations

Patients were consecutively recruited from the Department of Gastroenterology, the First Affiliated Hospital of Nanchang University (Nanchang, Jiangxi Province, China), between December 2013 and August 2019. The inclusion criteria were as follows: (1) Age ≥ 18 years; (2) diagnosis of cirrhosis (on account of previous hepatic pathology or clinical signs, imaging examinations, or laboratory and endoscopic presentation results); and (3) presence of acute decompensated events, including HE, gastroesophageal varices hemorrhage, development of large ascites, spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, and any combination of these. Patients with the following were excluded: (1) Primary liver carcinoma or other malignant tumors; (2) concurrent pregnancy; (3) infection with human immunodeficiency virus; (4) liver operations such as liver transplantation; and (5) loss to follow-up. The Ethics Committee of The First Affiliated Hospital of Nanchang University approved this study protocol (No. 2013-1202). Three hundred twenty-nine patients who were enrolled between December 2013 and September 2016 were assigned to the derivation cohort, and the other 164 patients were assigned to the validation cohort between October 2016 and August 2019 (approximate ratio of 2:1). This study follows the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis reporting guidelines for the development and validation of prediction models (Supplementary Table 1).

Data collection

Demographic information, laboratory tests, and clinical features were collected from electronic medical records. All laboratory tests were performed within 24 h after admission. The primary outcome was defined as death at the 28-d, 3-mo and 6-mo follow-up durations. The CTP score was computed according to ascites, prothrombin time (PT), serum bilirubin, albumin, and HE[6]. The MELD score was calculated as follows: MELD =9.6 × ln[serum creatinine (mg/dL)] + 3.8 × ln[total bilirubin (mg/dL)] + 11.2 × ln[PT (international normalized ratio, INR)] + 6.43 × (etiology: 0 if cholestatic or alcoholic, 1 otherwise)[7].

Treatment

For all patients, after the diagnosis of DLC was determined, standard medical therapies were used, such as endoscopic hemostasis therapy, antiviral treatment, liver-protecting therapy, albumin and plasma transfusion and prevention of complications such as HE and SBP.

Statistical analysis

Statistical analyses were performed with Statistical Product and Service Solutions (SPSS) software version 24.0 (SPSS Inc., Chicago, IL, United States). Continuous variables are expressed as the mean ± SD and were compared using an unpaired, 2-tailed t test or the Mann-Whitney test. Categorical variables were compared using the chi-squared test or Fisher’s exact test. Univariate risk factors that reached P < 0.2 were subjected to Cox regression analysis. The Age, mechanical ventilation application, MELD score, mean arterial blood pressure (MAP) and arterial oxygen partial pressure (PaO₂)/inhaled oxygen concentration (FiO₂) were used to construct the model. The final Cox regression model for fitness of the data and proportional hazards assumption was checked by the Schoenfeld residual test (the global test). The test revealed that the assumption was met with a P-value of the global test = 0.28.

The nomogram based on the results of previous Cox regression analyses was established using R version 3.3.2 (http://www.r-project.org/). The discrimination of the models was assessed according to the concordance index (C-index); the larger the C-index was, the more accurate the prognostic ability of the nomogram. The net reclassification index (NRI) quantifies the improvement in the predictive accuracy of the nomogram compared with the CTP and MELD scores. The integrated discrimination improvement index (IDI) evaluates different tangent lines that can be used to assess the overall improvement of the model and was calculated to assess the improvement of the nomogram compared with the CTP and MELD scores. In addition, NRI > 0 indicates that the new model is more accurate than the old model for prediction. The same is true for the IDI. Calibration curves were also drawn to evaluate the concordance between the predicted and observed probabilities. Decision curve analysis (DCA) was conducted to assess the clinical usefulness of the predictive nomogram by quantifying the net benefits at different threshold probabilities in both cohorts. In the present study, the R packages used included survival, survminer, rms, nricens, predictABEL, Hmisc, devtools, and ggDCA. All tests were two-sided, and differences were considered statistically significant when P < 0.05.

RESULTS

Baseline characteristics of the included patients

In total, 329 and 164 patients were included for analysis in the derivation and internal validation cohorts, respectively, and a flow diagram detailing the screening process is shown in Figure 1. The baseline characteristics of both cohorts are shown in Table 1. In the derivation and internal validation cohorts, the age ranges were 21-86 years (mean ± SD: 53.76 ± 11.64 years) and 31-91 years (mean ± SD: 57.38 ± 11.89 years), respectively. In the derivation and internal validation sets, the patients were predominantly men (253/329, 76.9% vs 116/164, 70.7%), the main etiology was hepatitis B virus (HBV) in 66.9% and 58.5% of patients, respectively, and the primary hospitalization reason was variceal bleeding (45.60% and 46.34%, respectively). When comparing the demographic and clinical characteristics between the derivation and validation sets, we found that the derivation set had shorter hospital stays (8.40 ± 5.88) and fewer patients with vasopressor use (88/329, 26.75%) and mechanical ventilation (MV) application (18/329, 5.47%) (P < 0.05). Moreover, the validation set had higher alanine aminotransferase (ALT), alkaline phosphatase (ALP), creatinine, and INR levels and higher CTP and MELD scores (P < 0.05). The validation set had higher 28-d, 3-mo and 6-mo risks of death than the derivation set (P < 0.05).

Figure 1 Flow diagram for selecting decompensated liver cirrhosis patients. HIV: Human immunodeficiency virus.

Table 1 Participant characteristics.

	Derivation cohort (n = 329)	Internal validation cohort (n = 164)	P
Age (yr), mean ± SD	53.76 ± 11.64	57.38 ± 11.89	0.001a
Male sex, n (%)	253 (76.90)	116 (70.70)	0.137
Hospitalization period (d), mean ± SD	8.40 ± 5.88	9.49 ± 4.69	0.026a
Liver cirrhosis etiology, n (%)
HBV	220 (66.90)	96 (58.50)	0.07
HCV	13 (3.95)	6 (3.66)	0.87
Alcoholic liver disease	52 (15.80)	30 (18.29)	0.49
Schistosomiasis cirrhosis	14 (4.25)	8 (4.88)	0.75
Primary biliary cirrhosis	3 (0.90)	5 (3.05)	0.08
Cryptogenic cirrhosis	27 (8.21)	18 (11.00)	0.31
Hospitalization reason, n (%)
Variceal bleeding	150 (45.60)	76 (46.34)	0.875
Hepatic encephalopathy	86 (26.14)	43 (26.22)	0.985
Infection	45 (13.68)	21 (12.80)	0.789
Ascites	28 (8.50)	13 (7.93)	0.825
Hepatorenal syndrome	20 (6.08)	11 (6.71)	0.787
Vasopressors	88 (26.75)	79 (48.17)	< 0.001a
HBeAg (+)	35 (10.64)	15 (9.15)	0.605
Mechanical ventilation	18 (5.47)	36 (21.95)	< 0.001a
Biochemical parameters
ALT, IU/L	22.00 (16.00-40.75)	29.00 (20.00-52.50)	< 0.001a
AST, IU/L	44.00 (31.00-90.50)	39.00 (28.00-74.00)	0.085
GGT, IU/L	27.00 (15.00-74.50)	29.00 (14.00-79.50)	0.982
ALP, IU/L	73.70 (55.00-112.00)	82.50 (56.25-138.75)	0.037a
Serum sodium, mmol/L	138.10 (135.00-141.00)	137.85 (134.03-140.98)	0.329
Creatinine, μmol/L	72.70 (59.35-93.20)	79.70 (63.55-115.00)	0.006a
INR	1.32 (1.21-1.54)	1.45 (1.24-1.74)	< 0.001a
Bilirubin, μmol/L	24.70 (15.80-42.80)	26.85 (16.03-58.25)	0.157
WBC, 10 × 9/L	6.39 (3.94-9.61)	6.81 (4.11-11.13)	0.11
Platelet, 10 × 9/L	74.50 (47.50-111.50)	73.80 (39.00-109.50)	0.245
PT, s	15.00 (13.80-17.20)	15.90 (13.40-19.20)	0.086
MAP, mmHg	83.00 (77.67-89.33)	82.17 (78.00-87.67)	0.472
PO2/FiO2	402.86 ± 118.57	388.28 ± 137.36	0.266
Albumin, g/L	28.41 ± 7.87	27.64 ± 6.18	0.256
CTP score	8 (7-10)	9 (7-11)	0.001a
MELD score	9.44 (5.96-13.52)	12.20 (7.77-16.67)	< 0.001a
Mortality, n (%)
28 d	41 (12.46)	47 (28.66)	< 0.001a
3 mo	65 (19.76)	69 (42.07)	< 0.001a
6 mo	75 (22.80)	73 (44.51)	< 0.001a

^aSignificant P value.

HBV: Hepatitis B virus; HCV: Hepatitis B virus; HBeAg: Hepatitis Be antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; INR: International normalized ratio; WBC: White blood cell; PT: Prothrombin time; MAP: Mean arterial blood pressure; PO₂/FiO₂: Arterial oxygen partial pressure/inhaled oxygen concentration; CTP score: Child-Turcotte-Pugh score; MELD score: Model for end-stage liver disease score.

Univariate and multivariate analyses

Univariate analysis showed that age, use of vasopressors, MV application, ALT, aspartate aminotransferase, γ-glutamyl transpeptidase, ALP, white blood cell count, MAP, PaO₂/FiO₂, CTP score and MELD score were significantly associated with the prognosis of DLC patients in the derivation set (P < 0.05, Table 2). Variables with significant differences by univariate analysis were subjected to multivariate Cox regression analyses. The results showed that only age, MV application and MELD score were independent risk factors for outcomes (HR: 1.028, 95%CI: 1.007-1.050; HR: 4.200, 95%CI: 1.975-8.932; HR: 1.080, 95%CI: 1.030-1.132, respectively), while MAP and PaO₂/FiO₂ were independent protective factors for mortality (HR: 0.979, 95%CI: 0.960-0.998; HR: 0.998, 95%CI: 0.995-1.000, respectively) (Table 2).

Table 2 Univariate and multivariate Cox regression analyses in decompensated liver cirrhosis patients from the derivation cohort (n = 329).

	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Age	1.021 (1.001-1.040)	0.037a	1.028 (1.007-1.050)	0.009a
Male sex	1.133 (0.653-1.967)	0.657
Vasopressors
No	Reference
Yes	1.643 (1.027-2.628)	0.038a
HBeAg
negative	Reference
positive	0.692 (0.301-1.594)	0.387
Mechanical ventilation
No	Reference
Yes	9.916 (5.486-17.922)	< 0.001a	4.200 (1.975-8.932)	< 0.001a
ALT	1.001 (1.000-1.002)	< 0.001a
AST	1.001 (1.000-1.001)	< 0.001a
GGT	1.001 (1.000-1.002)	0.090a
ALP	1.002 (1.001-1.003)	< 0.001a
Serum sodium	1.003 (0.982-1.026)	0.761
WBC	1.052 (1.030-1.073)	< 0.001a
Platelet	1.002 (0.999-1.004)	0.259
MAP	0.976 (0.967-0.996)	0.019a	0.979 (0.960-0.998)	0.031a
PO2/FiO2	0.996 (0.994-0.998)	< 0.001a	0.998 (0.995-1.000)	0.038a
CTP score	1.332 (1.214-1.462)	< 0.001a
MELD score	1.142 (1.107-1.178)	< 0.001a	1.080 (1.030-1.132)	0.002a

^aSignificant P value.

HBeAg: Hepatitis Be antigen; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase; WBC: White blood cell; MAP: Mean arterial blood pressure; PO₂/FiO₂: Arterial oxygen partial pressure/inhaled oxygen concentration; CTP score: Child-Turcotte-Pugh score; MELD score: Model for end-stage liver disease score.

Construction of a prognostic nomogram

Based on the results of multivariable Cox regression analyses, a nomogram including age, MV application, MAP, oxygenation index (OI; PaO₂/FiO₂) and MELD score was established to predict 28-d, 3-mo and 6-mo mortality (Figure 2). By assigning a weighted score to each of the independent prognostic parameters and using that value in the total point scale axis, the total score could be easily computed to assign the probability of survival for individual patients. For instance, a DLC patient aged 45 (15 points) with MV application (36 points), a MAP of 100 (25 points), an OI of 400 (21 points), and a MELD score of 15 (37.5 points) had a total of 134.5 points for a predicted 28-d, 3-mo, and 6-mo survival probability of 72%, 55% and 48%, respectively.

Figure 2 The nomogram for predicting 28-d, 3-mo and 6-mo survival probabilities of patients with decompensated liver cirrhosis. MV: Mechanical ventilation; MAP: mean arterial blood pressure; OI: Oxygenation index; MELD: Model for end-stage liver disease.

Performance of the model and clinical usefulness

We assessed the discriminative ability of our final model by using the C-index, and the C-index of the nomogram was 0.780 (95%CI: 0.670-0.889) in the derivation cohort, showing superior predictive performance to that of the CTP score (0.708, 95%CI: 0.596-0.820) or the MELD score (0.735, 95%CI: 0.609-0.860). The NRI and IDI were also determined to compare the efficiency between the nomogram and the two scores (Table 3). In the derivation cohort, when compared with the CTP score, the NRI values for 28-d, 3-mo, and 6-mo mortality were 0.419 (95%CI: 0.192-0.606), 0.355 (95%CI: 0.134-0.488) and 0.319 (95%CI: 0.081-0.481), respectively, and the IDI values for 28-d, 3-mo, and 6-mo mortality were 0.262 (95%CI: 0.181-0.394), 0.193 (95%CI: 0.118-0.285) and 0.178 (95%CI: 0.098-0.270), respectively. When compared with the MELD score, the NRI values for 28-d, 3-mo, and 6-mo mortality were 0.395 (95%CI: 0.214-0.548), 0.305 (95%CI: 0.080-0.417) and 0.281 (95%CI: 0.077-0.402), respectively, and the IDI values for 28-d, 3-mo, and 6-mo mortality were 0.133 (95%CI: 0.070-0.247), 0.081 (95%CI: 0.026-0.151) and 0.064 (95%CI: 0.023-0.133), respectively. The calibration curve of the nomogram is shown in Figure 3A-C, and the calibration plot revealed an adequate fit of the nomogram for predicting the risk of death. As shown in Figure 4A-C, the DCA showed that across the entire range of threshold probability, using the nomogram model to predict 28-d, 3-mo, and 6-mo survival adds more net benefit in clinical decision making.

Figure 3 The calibration curves of the nomogram for 28-d, 3-mo and 6-mo survival probabilities. A: Twenty-eight-day survival in the derivation group; B: Three-month survival in the derivation group; C: Six-month survival in the derivation group; D: Twenty-eight-day survival in the validation group; E: Three-month survival in the validation group; F: Six-month survival in the validation group; OS: Overall survival.

Figure 4 Decision curve analysis of the nomogram for the survival prediction of patients with decompensated liver cirrhosis. A: Twenty-eight-day survival in the derivation group; B: Three-month survival in the derivation group; C: Six-month survival in the derivation group; D: Twenty-eight-day survival in the validation group; E: Three-month survival in the validation group; F: Six-month survival in the validation group.

Table 3 The validation of the nomogram versus two scores by net reclassification index and integrated discrimination improvement index.

Index	Derivation cohort			Validation cohort
	Estimate	95%CI	P value	Estimate	95%CI	P value
NRI versus CTP
For 28-d mortality	0.419	0.192-0.606	< 0.001a	0.395	0.061-0.662	0.020a
For 3-mo mortality	0.355	0.134-0.488	0.007a	0.241	0.005-0.490	0.040a
For 6-mo mortality	0.319	0.081-0.481	< 0.001a	0.227	0.120-0.480	< 0.001a
NRI vs MELD
For 28-d mortality	0.395	0.214-0.548	< 0.001a	0.578	0.364-0.740	< 0.001a
For 3-mo mortality	0.305	0.080-0.417	0.013a	0.388	0.233-0.547	< 0.001a
For 6-mo mortality	0.281	0.077-0.402	0.007a	0.358	0.249-0.527	< 0.001a
IDI vs CTP
For 28-d mortality	0.262	0.181-0.394	< 0.001a	0.253	0.095-0.426	< 0.001a
For 3-mo mortality	0.193	0.118-0.285	< 0.001a	0.167	0.040-0.308	0.020a
For 6-mo mortality	0.178	0.098-0.270	< 0.001a	0.152	0.013-0.294	< 0.001a
IDI vs MELD
For 28-d mortality	0.133	0.070-0.247	< 0.001a	0.322	0.195-0.473	< 0.001a
For 3-mo mortality	0.081	0.026-0.151	< 0.001a	0.220	0.122-0.343	< 0.001a
For 6-mo mortality	0.064	0.023-0.133	< 0.001a	0.212	0.132-0.298	< 0.001a

^aSignificant P value.

NRI: Net reclassification index; CTP: Child-Turcotte-Pugh; MELD: Model for end-stage liver disease; IDI: Integrated discrimination improvement index.

Internal validation of the prognostic nomogram

The established model was internally validated by using the bootstrap validation method. When the established nomogram was used in the validation set, the C-index of the nomogram was 0.792 (95%CI: 0.698-0.886), with better predictive value than the CTP score (0.714, 95%CI: 0.602-0.826) and the MELD score (0.695, 95%CI: 0.575-0.815), indicating that the nomogram is suitable for estimating the outcome of DLC patients. In addition, the NRI and IDI values of the validation set also indicated that the present nomogram had improved accuracy compared to the CTP and MELD scores for predicting mortality (Table 3). Furthermore, the promising performance of the nomogram was also identified by calibration curve and decision curve analyses (Figures 3D-F and 4D-F).

DISCUSSION

In the present study, an easy-to-use novel nomogram was constructed to assess the prognosis of DLC patients. The proposed nomogram was derived from clinical and laboratory data to improve its clinical generality and applicability. This nomogram had superior predictive ability and clinical usefulness compared to the current prognostic score models, including the CTP and MELD scores. In addition, we adopted the internal validation cohort to reduce the influence of patients of different ages and other factors on the results.

In our derivation and validation cohorts, HBV was the predominant etiology among the DLC patients, which was in line with that in a previous study[12], indicating that HBV infection is a critical global health threat, particularly in Asia. Furthermore, the results showed that 150 (45.60%) and 76 (46.34%) patients were hospitalized for variceal bleeding in the derivation and validation sets, respectively. Variceal hemorrhage is a severe complication of portal hypertension in patients with cirrhosis and is associated with significant mortality[13]. Patients with variceal bleeding may develop other complications of cirrhosis and are at increased risk of developing circulatory dysfunction and bacterial infections that may lead to ACLF[4], which has high short-term mortality.

The CTP and MELD scores are commonly used to predict adverse outcomes in DLC patients. However, CTP is a subjective variable, including the presence or absence of HE and ascites[6]. The MELD score contains three indicators, namely, creatinine, INR, and bilirubin, but it lacks indicators of organ failure and may have a lower prognostication accuracy[14]. The proposed nomogram included age, MV application, MELD score, MAP, and OI. A previous study indicated that age was closely related to patient prognosis and that old age was a crucial factor for poor prognosis in cirrhosis[15]. MV is required for patients who develop acute respiratory failure, and it was identified as an independent factor related to intensive care unit (ICU) mortality in cirrhotic patients or patients with liver cirrhosis[16]. The results of a prospective cohort study that enrolled 592 cirrhotic patients admitted to the ICU revealed that patients who required MV had a poor prognosis, which was associated with organ failure[17]. The MELD score is based on three readily available biochemical variables: creatinine, serum bilirubin, and INR. It has been confirmed as a highly reliable predictor of short- and mid-term mortality in patients with cirrhosis awaiting liver transplantation[18]. However, the MELD score does not consider other conditions that are related to poor prognosis, such as organ failure, especially in critically ill patients. MAP is a reliable marker of circulatory function in ICU patients, particularly in patients with hemodynamic instability[19]. In this setting, circulatory dysfunction is the key feature of DLC[20]. A previous study showed that higher MAP values were related to acute kidney injury recovery in patients with DLC[21]. Patidar et al[22] evaluated the associations between MAP and poor ICU outcomes in critically ill cirrhotic patients and found that the risk of mortality intensely increased in patients whose MAP was below a threshold of 65 mmHg. The OI is PaO₂ divided by FiO₂ and is widely to assess acute respiratory distress syndrome (ARDS); the normal range is 400-500 mmHg[23]. Campbell et al[24] suggested that the OI is an independent predictor of ICU mortality in patients with cirrhosis and validated prognostic scoring tools for predicting ICU mortality.

In fact, the developed nomogram had superior discrimination power (C-index of 0.780) compared with using the CTP or MELD score alone. Moreover, a slightly higher C-index (0.792) was observed while performing internal validation in another set of cirrhotic patients. Based on the calibration plots, good calibration was observed. As indicated by the positive NRI and IDI, this nomogram is more accurate in predicting mortality than the CTP and MELD scores. In addition, according to DCA, the nomogram provided better clinical benefits than the conventional scores. Overall, the rationale of the selected variables was confirmed.

Nevertheless, our study has several limitations. First, this was a retrospective study; therefore, some potential bias may exist. Second, patients were enrolled from a single center. Third, the model only underwent internal validation. In the future, a prospective study is needed to validate the sensitivity and specificity of the nomogram.

CONCLUSION

In summary, we developed and validated a nomogram for predicting the survival probability of DLC patients. This simple nomogram had an adequate calibration and discrimination ability and good clinical utility. This nomogram may be helpful for promoting the early diagnosis and prevention of DLC.

ARTICLE HIGHLIGHTS

Research background

Decompensated liver cirrhosis (DLC) has high mortality, and there are some limitations when applying the common prognostic scores. Nomograms are widely used as prognostic models for many diseases.

Research motivation

Due to the worse prognosis, the overall survival of DLC has attracted much attention from clinicians. Thus, it is necessary to develop a prognostic model to evaluate the outcome of DLC patients.

Research objectives

This study aimed to develop and validate a novel and simple-to-use prognostic nomogram to assess the prognosis of DLC patients.

Research methods

A total of 493 DLC patients were included in this study and divided into a derivation group (n = 329) and a validation group (n = 164). According to the results of univariate and multivariate Cox regression analyses, a nomogram model was developed to predict the prognosis of DLC.

Research results

The nomogram was developed based on age, mechanical ventilation application, model for end-stage liver disease (MELD) score, mean arterial blood pressure and PaO₂/FiO₂. The C-indexes, calibration curves and decision curve analysis revealed that the nomogram model is a valid tool.

Research conclusions

We constructed a nomogram model that could accurately predict the prognosis of DLC patients and showed better prognostic performance than the CTP and MELD scores.

Research perspectives

This research established a nomogram that could predict prognosis in DLC patients. In addition, the nomogram was precisely evaluated by internal validation, which may be helpful to clinicians in clinical decision making.

ACKNOWLEDGEMENTS

We would like to thanks the National Natural Science Foundation of China (grant number: 81960120), the “Gan-Po Talent 555” Project of Jiangxi Province (GCZ (2012)-1) and the Jiangxi Clinical Research Center for Gastroenterology (20201ZDG02007).